================================================================
United States
Securities and Exchange Commission
Washington, D.C. 20549
----------------------
FORM 8-K
----------------------
Current Report
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
June 23, 1998 0-16132
Date of Report Commission File Number
(Date of earliest event reported)
Celgene Corporation
(Exact name of registrant as specified in its charter)
Delaware 22-2711928
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)
7 Powder Horn Drive
Warren, New Jersey 07059
-----------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(732) 271-1001
(Registrant's telephone number, including area code)
================================================================
Item 5. Other Events.
On June 23, 1998, Celgene Corporation (the "Company") entered
into a Stock Purchase Agreement (the "Stock Purchase Agreement")
with Biovail Laboratories Incorporated ("Biovail"), a Barbados
corporation incorporated under the International Business
Companies Act, 1991-24. Pursuant to the Stock Purchase
Agreement, Biovail purchased $2.5 million worth of the Company's
Common Stock, par value $.01 per share.
Item 7. Financial Statements, Unaudited Pro Forma Financial
Information and Exhibits.
(a) Not applicable.
(b) Not applicable
(c) Exhibits
10 Stock Purchase Agreement dated June 23, 1998
between Celgene Corporation and Biovail
Laboratories Incorporated.
99 Press Release, dated June 23, 1998.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Date: July 15, 1998 CELGENE CORPORATION
By: /s/ John W. Jackson
Name: John W. Jackson
Title: Chairman of the Board and
Chief Executive Officer